Individualized Hypoxia-guided Radiotherapy Combined With Standard Cisplatin-etoposide in Stage I-III SCLC
Hypoxic imaging with PET scans seems attractive for this purpose as hypoxia is associated
with resistance for radiotherapy and approximately 70 % of SCLC are severely hypoxic at
We hypothesize that it might be possible to use a selective boost in these patients to tumor
areas which are still hypoxic at the end of the standard chemo-radiotherapy to a dose of 45
Gy in 30 fractions in 3 weeks.
This way all SCLC (small cell lung cancer) patients can receive a safe, but higher dose of
radiotherapy to the whole tumor volume, while the most resistant areas receive the highest
This is a hypothesis generating trial designed to deliver at least the current standard
treatment to malignant tissue while defining patient selection criteria for future study.
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Cumulative local progression 18 months post-treatment as evaluated in a chest FDG-PET-CT scan
Dirk De Ruysscher, MD, PhD
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
HX4 in small cell lung cancer